The proof-of-concept study for the UniCAR system was conducted in AML indications targeting CD33, CD123, and later for the B-lineage antigen CD19 and common solid cancer targets of EGFR, PSMA, and PSCA [33,50,51]. This evidence concerns the gene CD19 and acute myeloid leukemia.